Evaxion Biotech Files 6-K, Incorporates by Reference

Ticker: EVAX · Form: 6-K · Filed: 2025-05-05T00:00:00.000Z

Sentiment: neutral

Topics: filing-update, registration-statement

Related Tickers: EVX

TL;DR

EVX files 6-K, standard update, nothing new for traders.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on May 5, 2025, to report its activities for the month of May 2025. The company is incorporated in Denmark and its principal executive offices are located in Hoersholm. This filing is incorporated by reference into several of Evaxion's existing registration statements on Forms S-8 and F-3, as well as various Form F-1 filings.

Why It Matters

This filing serves as an update and incorporates previous disclosures into ongoing registration statements, which is standard procedure for companies with active securities offerings or employee stock plans.

Risk Assessment

Risk Level: low — This is a routine filing that incorporates previous disclosures and does not contain new material financial or operational information.

Key Players & Entities

FAQ

What is the purpose of this Form 6-K filing by Evaxion Biotech A/S?

The Form 6-K is filed for the month of May 2025 and serves to incorporate by reference the report into Evaxion A/S's existing registration statements on various forms (S-8, F-3, F-1).

What is Evaxion Biotech A/S's commission file number?

Evaxion Biotech A/S's commission file number is 001-39950.

Where are Evaxion Biotech A/S's principal executive offices located?

Evaxion Biotech A/S's principal executive offices are located at Dr. Neergaards Vej 5f, DK-2970 Hoersholm, Denmark.

Which registration statements does this Form 6-K filing get incorporated into?

This filing is incorporated by reference into Evaxion A/S's registration statements on Form S-8 (File No. 333-255064), Form F-3 (File No. 333-265132), and multiple Form F-1 filings (File Nos. 333-266050, 333-276505, 333-279153, 333-283304) and Form F-3 (File No. 333-285778).

Does Evaxion Biotech A/S file annual reports under Form 20-F or Form 40-F?

Evaxion Biotech A/S indicates that it files annual reports under cover of Form 20-F.

From the Filing

0001171843-25-002744.txt : 20250505 0001171843-25-002744.hdr.sgml : 20250505 20250505084529 ACCESSION NUMBER: 0001171843-25-002744 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250505 FILED AS OF DATE: 20250505 DATE AS OF CHANGE: 20250505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25911178 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 4552656554 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_050525.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-39950 Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter) Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s (the “Company”) registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. Resolutions passed at the Annual General Meeting On April 30, 2025, Evaxion A/S (the “Company”) held its Annual General Meeting and 75,227,055 ordinary shares of the Company representing in total 23.82 % of the ordinary shares outstanding as of the date of the Annual General Meeting, were voted at the meeting. The final results of each of the agenda items submitted to a vote of the shareholders are as follows: Agenda Item 1: Election of the chairman of the meeting Attorney-at-law Lars Lüthjohan was elected as chairman of the meeting. Agenda Item 2: The board of directors' report on activities of the Company in the past year The General Meeting took note of the report of the board of directors on the activities of the Company in the past year. Agenda Item 3: Presentation of the audited annual report for adoption The General Meeting approved the Company’s audited annual report for the financial year 2024. Agenda Item 4: Resolution on the allocation of profit or coverage of loss, cf. the adopted annual report The General Meeting approved that the loss related to the financial year 2024 be transferred to the next financial year. Agenda Item 5: Election of members to the board of directors Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected as members of the board of directors . Helen Tayton-Martin was elected as a new board member. Agenda Item 6: Election of auditor EY Godkendt Revisionspartnerselskab was re-elected as the Company’s auditor in accordance with the recommendation from the board of directors. Agenda Item 7: Any motion from the board of directors and/or the shareholders 7a – proposal from the board of directors – new name The board of directors proposed changing of the Company’s name to “Evaxion A/S” and pro-posed that “Evaxion Biotech

View on Read The Filing